Quetiapine

Generic Name: Quetiapine

Brand Names: Seroquel

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₅N_₃O_₂S

CAS Number: 111974-69-7

Unique Ingredient Identifier: BGL0JSY5SI

Background: Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivi...

Indication: Quetiapine is used in the symptomatic treatment of schizophrenia. In addition, it may be used for the management of acute manic or mixed episodes in patients with bipolar I disorder, as a monotherapy or combined with other drugs. It may be used to manage depressive episodes in bipolar disorder. In addition to the above indications, quetiapine is used in comb...

Associated Conditions: Bipolar 1 Disorder, Depressive Episodes, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode

Associated Therapies: -

Clinical Trials

An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)

Completed

Conditions: Bipolar Disorder

Interventions: Drug: Risperidone
Drug: Iloperidone
Drug: Clozapine
Drug: Sertindole
Drug: Asenapine
Drug: Aripiprazole
Drug: Quetiapine
Drug: Olanzapine
Drug: Ziprasidone
Drug: Paliperidone
Drug: Lurasidone
Drug: Amisulpride
Drug: Zotepine

First Posted Date: 2011-12-23

Last Posted Date: 2022-02-04

Lead Sponsor: Organon and Co

Target Recruit Count: 42

Registration Number: NCT01498770

Quetiapine Compared With Placebo in the Management of Fibromyalgia

Phase 4

Completed

Conditions: Fibromyalgia

Interventions: Drug: Quetiapine

First Posted Date: 2011-10-25

Last Posted Date: 2014-07-09

Lead Sponsor: East Tennessee State University

Target Recruit Count: 42

Registration Number: NCT01458964

Locations: 🇺🇸
East Tennessee State University, Johnson City, Tennessee, United States

Comparison of the Pharmacokinetics of Three Generic Medications and Their Respective Brand Preparations

Phase 1

Conditions: Healthy

Interventions: Drug: Trazodone
Drug: Pindolol
Drug: Quetiapine
Procedure: Blood Collection

First Posted Date: 2011-07-22

Last Posted Date: 2011-07-22

Lead Sponsor: University of Ottawa

Target Recruit Count: 30

Registration Number: NCT01400165

Locations: 🇨🇦
University of Ottawa, Institute of Mental Health Research, Ottawa, Ontario, Canada

Comparative Effectiveness Study for Bipolar Disorder

Phase 4

Completed

Conditions: Bipolar Disorder

Interventions: Drug: Lithium
Drug: Quetiapine

First Posted Date: 2011-04-08

Last Posted Date: 2018-04-26

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 482

Registration Number: NCT01331304

Locations: 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States
🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
🇺🇸
Weill Cornell Medical College, New York, New York, United States

and more 8 locations

Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines

Phase 4

Terminated

Conditions: Generalized Anxiety Disorder
Major Depression

Interventions: Drug: quetiapine

First Posted Date: 2010-11-19

Last Posted Date: 2015-04-03

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 1

Registration Number: NCT01244711

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States

Adjunctive Quetiapine in the Treatment of Refractory Social Anxiety Disorder in Adults

Phase 4

Completed

Conditions: Social Anxiety Disorder

Interventions: Drug: Quetiapine

First Posted Date: 2010-10-19

Last Posted Date: 2017-04-18

Lead Sponsor: Cambridge Health Alliance

Target Recruit Count: 40

Registration Number: NCT01224067

Locations: 🇺🇸
Cambridge Health Alliance, Cambridge, Massachusetts, United States

Neurophysiologic Changes in Patients With Bipolar Depression

Phase 4

Conditions: Bipolar Depression

Interventions: Drug: Quetiapine

First Posted Date: 2010-10-01

Last Posted Date: 2013-11-21

Lead Sponsor: Seoul National University Bundang Hospital

Target Recruit Count: 60

Registration Number: NCT01213121

Locations: 🇰🇷
Department of Neuropsychiatry, Seoul National University Bundang Hospital, Seongnam-Si, Gyeonggi-Do, Korea, Republic of

Quetiapine in Melancholic Depression

Phase 4

Completed

Conditions: Depression
Healthy

Interventions: Drug: Quetiapine

First Posted Date: 2010-09-14

Last Posted Date: 2013-01-18

Lead Sponsor: University of Cincinnati

Target Recruit Count: 20

Registration Number: NCT01200901

Locations: 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States

Efficacy of Quetiapine XR Versus Placebo as Concomitant Treatment to Mood Stabilizers in the Control of Subsyndromal Symptoms of Bipolar Disorder

Phase 3

Completed

Conditions: Bipolar Disorder

Interventions: Drug: Placebo
Drug: Quetiapine

First Posted Date: 2010-09-09

Last Posted Date: 2012-09-19

Lead Sponsor: Centro de Investigación Biomédica en Red de Salud Mental

Target Recruit Count: 28

Registration Number: NCT01197846

Locations: 🇪🇸
Hospital Santa Creu I Sant Pau, Barcelona, Spain
🇪🇸
Hospital Clinic I Provincial, Barcelona, Spain
🇪🇸
Hosptial Benito Menni, Barcelona, Spain

and more 7 locations

Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital

Phase 4

Withdrawn

Conditions: Schizophrenia

Interventions: Drug: haloperidole
Drug: perphenazine
Drug: paliperidone palmitate
Drug: olanzapine
Drug: paliperidone
Drug: aripiprazole
Drug: risperidone
Drug: quetiapine

First Posted Date: 2010-09-01

Last Posted Date: 2013-07-08

Lead Sponsor: Ortho-McNeil Janssen Scientific Affairs, LLC

Registration Number: NCT01193166

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy